AFM13 (acimtamig)

About Affimed

Affimed is a German biopharmaceutical company focused on revolutionizing cancer treatment by engaging the innate immune system. Its core technology, the Redirected Optimized Cell Killing (ROCK®) platform, enables the creation of innate cell engagers (ICE®) that are designed to be highly potent and have a favorable safety profile. The company's most advanced programs, including AFM13 and AFM24, are in clinical development for various lymphomas and solid tumors, respectively, with key partnerships established with Genentech and Roivant to accelerate development and commercialization. As a publicly traded company, Affimed is strategically positioned to advance its pipeline and validate its innovative approach in immuno-oncology.

About Affimed

Affimed is a German biopharmaceutical company focused on revolutionizing cancer treatment by engaging the innate immune system. Its core technology, the Redirected Optimized Cell Killing (ROCK®) platform, enables the creation of innate cell engagers (ICE®) that are designed to be highly potent and have a favorable safety profile. The company's most advanced programs, including AFM13 and AFM24, are in clinical development for various lymphomas and solid tumors, respectively, with key partnerships established with Genentech and Roivant to accelerate development and commercialization. As a publicly traded company, Affimed is strategically positioned to advance its pipeline and validate its innovative approach in immuno-oncology.

Therapeutic Areas